Monday, July 28, 2014
Ventures is sticking with what works for its second
life sciences-only fund, which the firm closed last week at $500 million.
The fund, the
firm's ninth overall, was oversubscribed and was originally targeting $425
million. It will invest primarily in therapeutics companies and will focus on
areas like specialty products and Orphan diseases. Similar to Sofinnova